Literature DB >> 12963808

Endothelin-1 and osteoblastic metastasis.

Gregory R Mundy1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12963808      PMCID： PMC196846          DOI： 10.1073/pnas.2035063100

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  16 in total

Review 1.  Markers of bone turnover in prostate cancer.

Authors:  P Garnero
Journal:  Cancer Treat Rev       Date:  2001-06       Impact factor: 12.111

2.  Guanosine nucleotides inhibit different syndromes of PTHrP excess caused by human cancers in vivo.

Authors:  Wolfgang E Gallwitz; Theresa A Guise; Gregory R Mundy
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

3.  Antibodies to parathyroid hormone-related protein lower serum calcium in athymic mouse models of malignancy-associated hypercalcemia due to human tumors.

Authors:  S C Kukreja; D H Shevrin; S A Wimbiscus; P R Ebeling; J A Danks; C P Rodda; W I Wood; T J Martin
Journal:  J Clin Invest       Date:  1988-11       Impact factor: 14.808

4.  Tumor-derived platelet-derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer.

Authors:  Bing Yi; Paul J Williams; Marie Niewolna; Yakun Wang; Toshiyuki Yoneda
Journal:  Cancer Res       Date:  2002-02-01       Impact factor: 12.701

5.  Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo.

Authors:  A Achbarou; S Kaiser; G Tremblay; L G Ste-Marie; P Brodt; D Goltzman; S A Rabbani
Journal:  Cancer Res       Date:  1994-05-01       Impact factor: 12.701

6.  A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases.

Authors:  Juan Juan Yin; Khalid S Mohammad; Sanna M Käkönen; Stephen Harris; J Ruth Wu-Wong; Jerry L Wessale; Robert J Padley; I Ross Garrett; John M Chirgwin; Theresa A Guise
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-26       Impact factor: 11.205

7.  A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.

Authors:  Fred Saad; Donald M Gleason; Robin Murray; Simon Tchekmedyian; Peter Venner; Louis Lacombe; Joseph L Chin; Jeferson J Vinholes; J Allen Goas; Bee Chen
Journal:  J Natl Cancer Inst       Date:  2002-10-02       Impact factor: 13.506

8.  Expression of bone morphogenetic protein messenger RNAs by normal rat and human prostate and prostate cancer cells.

Authors:  S E Harris; M A Harris; P Mahy; J Wozney; J Q Feng; G R Mundy
Journal:  Prostate       Date:  1994-04       Impact factor: 4.104

Review 9.  The role of stromal-epithelial interaction in normal and malignant growth.

Authors:  L W Chung
Journal:  Cancer Surv       Date:  1995

10.  Markers of bone turnover for the management of patients with bone metastases from prostate cancer.

Authors:  P Garnero; N Buchs; J Zekri; R Rizzoli; R E Coleman; P D Delmas
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640
View more
  10 in total

1.  Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial.

Authors:  David I Quinn; Catherine M Tangen; Maha Hussain; Primo N Lara; Amir Goldkorn; Carol M Moinpour; Mark G Garzotto; Philip C Mack; Michael A Carducci; J Paul Monk; Przemyslaw W Twardowski; Peter J Van Veldhuizen; Neeraj Agarwal; Celestia S Higano; Nicholas J Vogelzang; Ian M Thompson
Journal:  Lancet Oncol       Date:  2013-07-17       Impact factor: 41.316

2.  Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421.

Authors:  Primo N Lara; Benjamin Ely; David I Quinn; Philip C Mack; Catherine Tangen; Erik Gertz; Przemyslaw W Twardowski; Amir Goldkorn; Maha Hussain; Nicholas J Vogelzang; Ian M Thompson; Marta D Van Loan
Journal:  J Natl Cancer Inst       Date:  2014-02-24       Impact factor: 13.506

3.  Endothelin-A receptor antagonists in prostate cancer treatment-a meta-analysis.

Authors:  Longwei Qiao; Yuting Liang; Na Li; Xiaoxia Hu; Dongwei Luo; Junxia Gu; Yaojuan Lu; Qiping Zheng
Journal:  Int J Clin Exp Med       Date:  2015-03-15

4.  Osteoblast differentiation profiles define sex specific gene expression patterns in craniosynostosis.

Authors:  Sarah S Park; Richard P Beyer; Matthew D Smyth; Christine M Clarke; Andrew E Timms; Theo K Bammler; Brendan D Stamper; Brigham H Mecham; Jennifer A Gustafson; Michael L Cunningham
Journal:  Bone       Date:  2015-03-07       Impact factor: 4.398

5.  Endothelin receptor antagonists: rationale, clinical development, and role in prostate cancer therapeutics.

Authors:  Snehal G Thakkar; Toni K Choueiri; Jorge A Garcia
Journal:  Curr Oncol Rep       Date:  2006-03       Impact factor: 5.075

6.  Role of Endothelin-1 in a Syndrome of Myelofibrosis and Osteosclerosis.

Authors:  Ralph Yachoui; Jasmin Kristianto; Kajal Sitwala; Robert D Blank
Journal:  J Clin Endocrinol Metab       Date:  2015-09-10       Impact factor: 5.958

7.  The future in advanced prostate cancer: take your partners or is the last dance for me?

Authors:  David I Quinn
Journal:  Rev Urol       Date:  2004

8.  Dickkopf-1 (DKK-1) stimulated prostate cancer growth and metastasis and inhibited bone formation in osteoblastic bone metastases.

Authors:  Nanda K Thudi; Chelsea K Martin; Sridhar Murahari; Sherry T Shu; Lisa G Lanigan; Jillian L Werbeck; Evan T Keller; Laurie K McCauley; Joseph J Pinzone; Thomas J Rosol
Journal:  Prostate       Date:  2010-10-18       Impact factor: 4.104

9.  Zoledronic acid decreased osteolysis but not bone metastasis in a nude mouse model of canine prostate cancer with mixed bone lesions.

Authors:  Nanda K Thudi; Chelsea K Martin; Murali V P Nadella; Soledad A Fernandez; Jillian L Werbeck; Joseph J Pinzone; Thomas J Rosol
Journal:  Prostate       Date:  2008-07-01       Impact factor: 4.104

Review 10.  New developments in the medical management of prostate cancer.

Authors:  Manish Kohli; Donald J Tindall
Journal:  Mayo Clin Proc       Date:  2010-01       Impact factor: 7.616
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.